GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jiang Xi Sanxin Medtec Co Ltd (SZSE:300453) » Definitions » ROC %

Jiang Xinxin Medtec Co (SZSE:300453) ROC % : 19.71% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jiang Xinxin Medtec Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Jiang Xinxin Medtec Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was 19.71%.

As of today (2025-04-04), Jiang Xinxin Medtec Co's WACC % is 9.83%. Jiang Xinxin Medtec Co's ROC % is 16.53% (calculated using TTM income statement data). Jiang Xinxin Medtec Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Jiang Xinxin Medtec Co ROC % Historical Data

The historical data trend for Jiang Xinxin Medtec Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiang Xinxin Medtec Co ROC % Chart

Jiang Xinxin Medtec Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.37 18.84 18.30 15.83 16.66

Jiang Xinxin Medtec Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.88 14.77 14.68 16.86 19.71

Jiang Xinxin Medtec Co ROC % Calculation

Jiang Xinxin Medtec Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=283.401 * ( 1 - 10.27% )/( (1518.24 + 1535.336)/ 2 )
=254.2957173/1526.788
=16.66 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2030.808 - 385.761 - ( 362.856 - max(0, 564.953 - 691.76+362.856))
=1518.24

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2222.71 - 441.015 - ( 468.328 - max(0, 577.596 - 823.955+468.328))
=1535.336

Jiang Xinxin Medtec Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=332.432 * ( 1 - 8.04% )/( (1566.835 + 1535.336)/ 2 )
=305.7044672/1551.0855
=19.71 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2158.083 - 416.483 - ( 404.123 - max(0, 560.385 - 735.15+404.123))
=1566.835

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2222.71 - 441.015 - ( 468.328 - max(0, 577.596 - 823.955+468.328))
=1535.336

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiang Xinxin Medtec Co  (SZSE:300453) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Jiang Xinxin Medtec Co's WACC % is 9.83%. Jiang Xinxin Medtec Co's ROC % is 16.53% (calculated using TTM income statement data). Jiang Xinxin Medtec Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Jiang Xinxin Medtec Co ROC % Related Terms

Thank you for viewing the detailed overview of Jiang Xinxin Medtec Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiang Xinxin Medtec Co Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Fushan Avenue, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province, Nanchang, CHN, 330200
Jiang Xi Sanxin Medtec Co Ltd is engaged in researching and developing, manufacturing and marketing of medical devices. Its products include four series: blood purification, indwelling catheters, injections, infusion and blood transfusion. Blood purification products are used in clinical dialysis treatment for uremic patients. Indwelling catheter products represented by venous indwelling needles, positive pressure indwelling needles, central venous catheters. Injectable products mainly include self-destructing syringes, retracting self-destructing syringes, conjoined syringes.
Executives
Zhang Lin Supervisors
Le Zhen Rong Executives
Mao Zhi Ping Directors, executives
Yu Zhen Zhu Supervisors
Peng Yi Xing Director
Liu Ming Securities Affairs Representative
Wan Xiao Ping Director
Wang Qin Hua Supervisors
Xiong Yan Supervisors

Jiang Xinxin Medtec Co Headlines

No Headlines